. 2011 Jul;3(4):185–205. doi: 10.1177/1758834011409973

Table 2.

Predictive biomarkers in early-stage non-small cell lung cancer.

Study	Biomarker (assay)	Study design (LOE)	Number of patients/ specimens	Stage of disease	Biomarker status	HR for overall survival (p value); p value for interaction test
[Kamal et al. 2010]	MSH2 (IHC)	Retrospective analysis within IALT study (ΙΙ)	1867/673	I–III	Low expression vs high expression (H-score = 3)	0.76 (0.03) vs 1.12 (0.48); 0.06
[Olaussen et al. 2006]	ERCC1 (IHC)	Retrospective analysis within IALT study (ΙΙ)	1867/761	I–III	Negative expression vs positive expression (H-score > median value)	0.65 (0.002) vs 1.14 (0.40); 0.009
[Filipits et al. 2007b]	p27^Kip1 (IHC)	Retrospective analysis within IALT study (ΙΙ)	1867/778	I–III	Negative expression vs positive expression (H-score > median value)	0.66 (0.006) vs 1.09 (0.54); 0.02
[Tsao et al. 2007]	p53 (IHC)	Retrospective analysis within NCIC CTG-JBR.10 (ΙΙ)	482/253	IB–II	Positive expression (staining score ≥15%) vs negative	0.54 (0.02) vs 1.40 (0.26); 0.02
[Pirker et al. 2007]	ERCC1/p27^Kip1 (IHC)	Retrospective analysis within IALT study (ΙΙ)	1867/778	I–III	Both negative vs both positive	0.52 (95% CI: 0.36-0.74) vs 1.27 (95% CI: 0.87-1.84); not specified
[Kamal et al. 2010]	MSH2/ERCC1 (IHC)	Retrospective analysis within IALT study (ΙΙ)	1867/658	I–III	Both low vs both high	0.65 (0.01) vs 1.32 (0.19); 0.01
[Kamal et al. 2010]	MSH2/p27^Kip1 (IHC)	Retrospective analysis within IALT study (ΙΙ)	1867/not defined	I–III	Both low vs both high	0.65 (0.01) vs 1.31 (0.22); 0.01

ERCC1, endonuclease excision repair cross-complementing 1; HR, hazard ratio; IALT, International Adjuvant Lung Cancer Trial; IHC, immunohistochemistry; LOE, level of evidence for grading clinical utility of tumor markers [Hayes et al. 1996]; MSH2, MutS homolog 2; NCIC CTG, National Cancer Institute of Canada Clinical Trials Group; p27^Kip1, cyclin-dependent kinase inhibitor 1B; p53, tumor protein 53; vs, versus.